<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This article about treatment and prevention of <z:hpo ids='HP_0001297'>stroke</z:hpo> is part of the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) </plain></SENT>
<SENT sid="1" pm="."><plain>Grade 1 recommendations are strong and indicate that the benefits do, or do not, outweigh risks, burden, and costs </plain></SENT>
<SENT sid="2" pm="."><plain>Grade 2 suggests that individual patients' values may lead to different choices (for a full understanding of the grading, see the "Grades of Recommendations" chapter by Guyatt et al, CHEST 2008; 133:123S-131S) </plain></SENT>
<SENT sid="3" pm="."><plain>Among the key recommendations in this chapter are the following: For patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo>, we recommend administration of IV tissue plasminogen activator (tPA) if treatment is initiated within 3 h of clearly defined symptom <z:hpo ids='HP_0003674'>onset</z:hpo> (Grade 1A) </plain></SENT>
<SENT sid="4" pm="."><plain>For patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> of &gt; 3 h but &lt; 4.5 h, we suggest clinicians do not use IV tPA (Grade 2A) </plain></SENT>
<SENT sid="5" pm="."><plain>For patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0003674'>onset</z:hpo> of &gt; 4.5 h, we recommend against the use of IV tPA (Grade 1A) </plain></SENT>
<SENT sid="6" pm="."><plain>For patients with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> who are not receiving thrombolysis, we recommend early aspirin therapy (Grade 1A) </plain></SENT>
<SENT sid="7" pm="."><plain>For <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> patients with restricted mobility, we recommend prophylactic low-dose subcutaneous <z:chebi fb="5" ids="28304">heparin</z:chebi> or low-molecular-weight <z:chebi fb="0" ids="24505">heparins</z:chebi> (Grade 1A) </plain></SENT>
<SENT sid="8" pm="."><plain>For long-term <z:hpo ids='HP_0001297'>stroke</z:hpo> prevention in patients with noncardioembolic <z:hpo ids='HP_0001297'>stroke</z:hpo> or <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo> (<z:hpo ids='HP_0002326'>TIA</z:hpo>) [ie, atherothrombotic, lacunar, or cryptogenic], we recommend treatment with an antiplatelet agent (Grade 1A), including aspirin (recommended dose, 50-100 mg/d), the combination of aspirin and extended-release <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> (25 mg/200 mg bid), or <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> (75 mg qd) </plain></SENT>
<SENT sid="9" pm="."><plain>In these patients, we recommend use of the combination of aspirin and extended-release <z:chebi fb="0" ids="4653">dipyridamole</z:chebi> (25/200 mg bid) over aspirin (Grade 1A) and suggest <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> over aspirin (Grade 2B), and recommend avoiding long-term use of the combination of aspirin and <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> (Grade 1B) </plain></SENT>
<SENT sid="10" pm="."><plain>For patients who are allergic to aspirin, we recommend <z:chebi fb="0" ids="37941">clopidogrel</z:chebi> (Grade 1A) </plain></SENT>
<SENT sid="11" pm="."><plain>In patients with <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> and a recent <z:hpo ids='HP_0001297'>stroke</z:hpo> or <z:hpo ids='HP_0002326'>TIA</z:hpo>, we recommend long-term oral anticoagulation (target international normalized ratio, 2.5; range, 2.0 to 3.0) [Grade 1A] </plain></SENT>
<SENT sid="12" pm="."><plain>In patients with venous sinus <z:mp ids='MP_0005048'>thrombosis</z:mp>, we recommend unfractionated <z:chebi fb="5" ids="28304">heparin</z:chebi> (Grade 1B) or low-molecular-weight <z:chebi fb="5" ids="28304">heparin</z:chebi> (Grade 1B) over no <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy during the <z:hpo ids='HP_0011009'>acute</z:hpo> phase </plain></SENT>
</text></document>